Boehringer Ingelheim and Eli Lilly and Company announce acceptance of European marketing authorisation application for

  Boehringer Ingelheim and Eli Lilly and Company announce acceptance of
  European marketing authorisation application for investigational Type 2
  Diabetes treatment empagliflozin*

European Medicines Agency has accepted for review a marketing authorisation
application for the sodium glucose cotransporter-2, empagliflozin

Business Wire

INGELHEIM, Germany -- March 26, 2013

EX US & UK
Medical Media Only

Boehringer Ingelheim and Eli Lilly and Company today announced the European
Medicines Agency (EMA) has accepted for review a marketing authorisation
application (MAA) for the investigational sodium glucose cotransporter-2
(SGLT2) inhibitor, empagliflozin, for the treatment of Type 2 Diabetes (T2D)
in adults. The acceptance of the MAA marks the beginning of the review process
in the European Union for this potential oral diabetes treatment.

“We are pleased with the promising results shown in clinical trials of
empagliflozin and are delighted that EMA has accepted our marketing
authorisation application,” said Prof.Klaus Dugi, Corporate Senior Vice
President Medicine,BoehringerIngelheim. “Type 2 Diabetes is a critical
health issue and new treatment options are needed in order to help patients
better manage their condition.”

A New Drug Application (NDA) for empagliflozin was recently submitted to the
Food and Drug Administration (FDA) in the United States for the treatment of
Type 2 Diabetes mellitus (T2D) in adults.

Empagliflozin is part of a class of drugs being investigated for the reduction
of blood glucose levels in adults with T2D. In clinical trials to date, SGLT2
inhibitors have been shown to reduce blood glucose by removing excess glucose
independently of beta cell function and insulin resistance.

*Empagliflozin is an investigational compound. Its safety and efficacy have
not yet been fully established

                                    ~ends~

Please click on the link below for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/26_march_2013_empagliflozin.html

*Empagliflozin is an investigational compound. Its safety and efficacy have
not yet been fully established

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130326005988/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50597242&lang=en

Contact:

Ute E. Schmidt
Launch and Established Products CVM
Boehringer Ingelheim GmbH
Email: press@boehringer-ingelheim.com
Phone: +49 (6132) 77-97296
OR
Tammy Hull
Communications Manager
Lilly Diabetes
Email: hullta@lilly.com
Phone: +1 (317) 651-9116